Chris Howerton
Stock Analyst at Jefferies
(2.68)
# 2,194
Out of 5,099 analysts
69
Total ratings
46.3%
Success rate
19.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.86 | +36.64% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $67.10 | +17.73% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.61 | +53.26% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.55 | +291.94% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.25 | +15,579.29% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $19.70 | +3,554.82% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.61 | -68.85% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $22.45 | -55.46% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $21.43 | -48.67% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $24.00 | +66.67% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $38.55 | +58.26% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $146.40 | -38.52% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $6.52 | +84.19% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.80 | +2,407.84% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $28.00 | +135.71% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.88 | +274.15% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.01 | +1,979.21% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.99 | +2,127.96% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $26.81 | -21.67% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $17.00 | +3,311.76% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.98 | +2,930.30% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $83.48 | -80.83% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $89.78 | -69.93% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $3.83 | +31,231.59% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.86
Upside: +36.64%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $67.10
Upside: +17.73%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.61
Upside: +53.26%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.55
Upside: +291.94%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.25
Upside: +15,579.29%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $19.70
Upside: +3,554.82%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.61
Upside: -68.85%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $22.45
Upside: -55.46%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $21.43
Upside: -48.67%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $24.00
Upside: +66.67%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $38.55
Upside: +58.26%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $146.40
Upside: -38.52%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $6.52
Upside: +84.19%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.80
Upside: +2,407.84%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $28.00
Upside: +135.71%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.88
Upside: +274.15%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.01
Upside: +1,979.21%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.99
Upside: +2,127.96%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $26.81
Upside: -21.67%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $17.00
Upside: +3,311.76%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.98
Upside: +2,930.30%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $83.48
Upside: -80.83%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $89.78
Upside: -69.93%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $3.83
Upside: +31,231.59%